Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other financing activities (2016 - 2023)

Historic Other financing activities for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to $1.8 million.

  • Spyre Therapeutics' Other financing activities fell 1199.8% to $1.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $6.5 million, marking a year-over-year decrease of 2214.21%. This contributed to the annual value of $7.1 million for FY2022, which is 1153.27% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Other financing activities of $1.8 million as of Q2 2023, which was down 1199.8% from $1.7 million recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Other financing activities ranged from a high of $2.1 million in Q3 2021 and a low of $1.1 million during Q1 2019
  • Its 5-year average for Other financing activities is $1.7 million, with a median of $1.7 million in 2020.
  • Per our database at Business Quant, Spyre Therapeutics' Other financing activities surged by 3614.86% in 2020 and then tumbled by 3185.29% in 2022.
  • Over the past 5 years, Spyre Therapeutics' Other financing activities (Quarter) stood at $1.2 million in 2019, then skyrocketed by 36.15% to $1.6 million in 2020, then rose by 29.9% to $2.1 million in 2021, then crashed by 31.85% to $1.4 million in 2022, then increased by 24.39% to $1.8 million in 2023.
  • Its Other financing activities stands at $1.8 million for Q2 2023, versus $1.7 million for Q1 2023 and $1.4 million for Q4 2022.